• 1
    Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2012;12.
  • 2
    Savage PM, Sita-Lumsde A, Dickson S, Iyer R, Everard J, Coleman R, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol 2013;33:40611.
  • 3
    Kang WD, Choi HS, Kim SM. Prediction of persistent gestational trophobalstic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole. Gynecol Oncol 2012;124:2503.
  • 4
    Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010;376:71729.
  • 5
    Bagshawe KD, Dent J, Webb J. Hydatidiform mole in England and Wales. Lancet 1986;673:197383.
  • 6
    Wolfberg AJ, Feltmate C, Goldstein DP, Berkowitz RS, Lieberman E. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy. Obstet Gynecol 2004;104:5514.
  • 7
    Cissé CT, Sall A, Moreau JC, Mendez V, Touré M, Afoutou JM. Prévention du choricarcinome postmolaire en milieu africain: exemple du Sénégal. La Lettre du Gynécologue 2005;307:814.
  • 8
    FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2002;77:2857.
  • 9
    Wang S, An R, Han X, Zhu K, Xue Y. Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences. Gynecol Oncol 2006; 103:11058.
  • 10
    Berkowitz RS, Goldstein DP. Presentation and management of molar pregnancy. In: Hancock BW, Seckl MJ, Berkowitz RS, Cole LA, editors. Gestational Trophoblastic Disease, 3rd edn. London: International Society for the Study of Trophoblastic Diseases, 2009. pp. 24976.
  • 11
    CNGOF, ANM, SFMP. Recommandations de bonne pratique clinique. Maladies trophoblastiques gestationnelles: Diagnostic et prise en charge. Argumentaire. Boullogne-Billancourt: Institut National du Cancer, 2010.
  • 12
    Golfier F, Guastalla J-P, Trillet-Lenoir V, Massardier J, Pavic M, Schott AM, et al. Môle hydatiforme et tumeurs trophoblastiques gestationnelles. Oncologie 2008;10:60411.
  • 13
    Uberti EMH, Fajardo Mdo C, da Cunha AGV, Rosa MW, Ayub ACK, Graudenz Mda S, et al. Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment. Gynecol Oncol 2009;114:299305.
  • 14
    Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009;112:65462.
  • 15
    Fu J, Fang F, Xie L, Chen H, He F, Wu T, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2012;10.
  • 16
    Feltmate CM, Batorfi J, Fulop V, Goldstein DP, Doszpod J, Berkowitz RS, et al. Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. Obstet Gynecol 2003;101:7326.
  • 17
    Wolfberg AJ, Growdon WB, Feltmate CM, Goldstein DP, Genest DR, Chinchilla ME, et al. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy. Obstet Gynecol 2006;108:3936.
  • 18
    Lavie I, Rao GG, Diego HC, Miller DS, Schorge JO. Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles. Am J Obstet Gynecol 2005;192:13624.
  • 19
    Bartorfi J, Vegh G, Szepesi J, Szigetvari I, Doszpod J, Fulop V. How long should patients be followed after molar pregnancy? Analysis of serum hCG follow-up data. Obstet Gynecol 2004;112:957.
  • 20
    Wielsma S, Kerkmeijer L, Bekkers R, Pyman J, Tan J, Quinn M. Persistent trophoblastic disease following partial molar pregnancy. Aust NZ J Obstet Gynecol 2006;46:11923.
  • 21
    Kerkmeijer L, Wielsma S, Bekkers R, Pyman J, Tan J, Quinn M. Guidelines following hydatidiform mole: a reappraisal. Aust NZ J Obstet Gynecol 2006;46:11218.
  • 22
    Kerkmeijer LGW, Wielsma S, Massuger LFAG, Sweep FCGJ, Thomas CMG. Recurrent gestational trophoblastic disease after hCG normalisation following hydatidiform mole in The Netherlands. Gynecol Oncol 2007;106:1426.